{"schema_version":"1","generated_at":"2026-11-21T19:50:25.905Z","data_as_of":null,"url":"https://www.findmykol.com/kol/daniel-nikcevich","json_url":"https://www.findmykol.com/kol/daniel-nikcevich/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"daniel-nikcevich","name":"Daniel Nikcevich","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"Essentia Health","institution_url":"https://www.findmykol.com/institution/essentia-health","city":"Duluth","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Daniel Nikcevich is a Hematology physician affiliated with Essentia Health. OpenAlex indexes 87 publications with 3,076 citations (h-index 26).","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":87,"cited_by_count":3076,"h_index":26,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":68.49,"payment_count":1},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":26,"payment_count":1},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2022,"amount_usd":22.2,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":10,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":33.5,"classes_total":8,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":8.8,"drugs":[{"name":"Anastrozole","share_pct":78.5},{"name":"Letrozole","share_pct":12.8},{"name":"Exemestane","share_pct":8.7}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":5.7,"drugs":[{"name":"Imbruvica","share_pct":75},{"name":"Imatinib Mesylate","share_pct":25}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":30,"classes_total":6,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":11.6,"drugs":[{"name":"Oxycodone Hcl","share_pct":69.5},{"name":"Hydromorphone Hcl","share_pct":16.2},{"name":"Fentanyl","share_pct":8.1},{"name":"Tramadol Hcl","share_pct":6.1}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":11.4,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":98}]},{"area":"Metabolism & gastrointestinal","share_pct":13.5,"classes_total":5,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":5.9,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":32},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":2.8,"drugs":[{"name":"Ondansetron Hcl","share_pct":72.9},{"name":"Ondansetron Odt","share_pct":27.1}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2005,"last":2014},"rows_total":11,"shown":3,"withheld":8,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"U10CA035269","title":"Duluth Community Clinical Oncology Program","fiscal_year":2014,"amount_usd":"111679","organization":"ESSENTIA INSTITUTE OF RURAL HEALTH","source_url":"https://reporter.nih.gov/quickSearch/U10CA035269"},{"project":"U10CA035269","title":"Duluth Community Clinical Oncology Program","fiscal_year":2013,"amount_usd":"770073","organization":"ESSENTIA INSTITUTE OF RURAL HEALTH","source_url":"https://reporter.nih.gov/quickSearch/U10CA035269"},{"project":"U10CA035269","title":"Duluth Community Clinical Oncology Program","fiscal_year":2012,"amount_usd":"538966","organization":"ESSENTIA INSTITUTE OF RURAL HEALTH","source_url":"https://reporter.nih.gov/quickSearch/U10CA035269"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.01667","status":"verified"},{"title":"Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])","year":2021,"journal":"European Journal of Cancer","source_url":"https://doi.org/10.1016/j.ejca.2021.03.025","status":"verified"},{"title":"Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)","year":2018,"journal":"Breast Cancer Research and Treatment","source_url":"https://doi.org/10.1007/s10549-018-4713-2","status":"verified"},{"title":"Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study","year":2017,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.24762","status":"verified"},{"title":"Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)","year":2017,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.24824","status":"verified"}],"source":"works"},"similar":[{"name":"Charles Gessert","slug":"charles-gessert","institution":"Essentia Health","specialty":"Pediatrics","url":"https://www.findmykol.com/kol/charles-gessert","json_url":"https://www.findmykol.com/kol/charles-gessert/profile.json"},{"name":"Nancy Sudak","slug":"nancy-sudak","institution":"Essentia Health","specialty":"Family Medicine","url":"https://www.findmykol.com/kol/nancy-sudak","json_url":"https://www.findmykol.com/kol/nancy-sudak/profile.json"},{"name":"Jesus Vera Aguilera","slug":"jesus-vera-aguilera","institution":"Essentia Health","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jesus-vera-aguilera","json_url":"https://www.findmykol.com/kol/jesus-vera-aguilera/profile.json"},{"name":"David C. Herman","slug":"david-herman","institution":"Essentia Health","url":"https://www.findmykol.com/kol/david-herman","json_url":"https://www.findmykol.com/kol/david-herman/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Faith Davies","slug":"faith-davies","institution":"NYU Langone Health","specialty":"Hematology","url":"https://www.findmykol.com/kol/faith-davies","json_url":"https://www.findmykol.com/kol/faith-davies/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"funding":8,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}